Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor

Precision medicines exert selective pressure on tumor cells that leads to the preferential growth of resistant subpopulations, necessitating the development of next generation therapies to treat the evolving cancer. The PIK3CA/AKT/mTOR pathway is one of the most commonly activated pathways in human...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrik-Outmezguine, Vanessa S., Okaniwa, Masanori, Yao, Zhan, Novotny, Chris J., McWhirter, Claire, Banaji, Arpitha, Won, Helen, Wong, Wai, Berger, Mike, de Stanchina, Elisa, Barratt, Derek G., Cosulich, Sabina, Klinowska, Teresa, Rosen, Neal, Shokat, Kevan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902179/
https://www.ncbi.nlm.nih.gov/pubmed/27279227
http://dx.doi.org/10.1038/nature17963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902179/
https://www.ncbi.nlm.nih.gov/pubmed/27279227
http://dx.doi.org/10.1038/nature17963

Ejemplares similares